Consolidated Gems, Inc.

Equities

CGEM

US2092631025

Non-Gold Precious Metals & Minerals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

Apr. 17	BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating	MT
Apr. 16	HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Consolidated Gems, Inc.

BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating	Apr. 17	MT
HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating	Apr. 16	MT
Wedbush Raises Cullinan Oncology Price Target to $36 From $30, Maintains Outperform Rating	Apr. 16	MT
William Blair Initiates Cullinan Oncology With Outperform Rating	Apr. 15	MT
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	Mar. 14	MT
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	Mar. 01	MT
Wedbush Starts Cullinan Oncology With Outperform Rating, $30 Price Target	Feb. 15	MT
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	Feb. 05	MT
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	Jan. 31	MT
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	Dec. 15	MT
JonesTrading Initiates Cullinan Oncology With Buy Rating, Price Target is $22	23-10-06	MT
TD Cowen Starts Cullinan Oncology at Outperform	23-06-15	MT
Insider Sell: Cullinan Oncology	23-06-08	MT
HC Wainwright Adjusts Price Target on Cullinan Oncology to $49 From $50, Maintains Buy Rating	23-05-12	MT
Cullinan Oncology Gets FDA Clearance for CLN-617 Study	23-03-27	MT
Cullinan Oncology's Q4 Loss Narrows	23-03-09	MT
Cullinan Oncology to Pay $25 Million for License Agreement With Harbour BioMed	23-02-14	MT
Morgan Stanley Adjusts Price Target on Cullinan Oncology to $19 From $27, Maintains Overweight Rating	23-02-03	MT
Cullinan Oncology Says US FDA Approves Investigational New Drug Application for CLN-978	23-01-24	MT
BTIG Initiates Cullinan Oncology With Buy Rating, Sets Price Target at $20	22-11-21	MT
Cullinan Oncology Posts Wider Q3 Loss; Cash, Equivalents Decline	22-11-14	MT
Cullinan Oncology Raises Stake in Cullinan MICA Unit to 92%	22-10-25	MT
Cullinan Oncology Swings to Profit in Q2	22-08-10	MT
Insider Sell: Cullinan Oncology	22-07-26	MT
Insider Sell: Cullinan Oncology	22-07-21	MT

Chart Consolidated Gems, Inc.

Duration

Period

More charts

Company Profile

Consolidated Gems Inc is an Australia-based company. The Company is a provider of business support services.

Sector

Non-Gold Precious Metals & Minerals

More about the company

Sector Other Precious Metals & Minerals

	1st Jan change	Capi.
CONSOLIDATED GEMS, INC.	-.--%	4M
IMPALA PLATINUM HOLDINGS LIMITED	-5.53%	4.08B
SIBANYE STILLWATER LIMITED	-10.04%	3.33B
SINO-PLATINUM METALS CO.,LTD	-0.56%	1.5B
SILVERCREST METALS INC.	+33.14%	1.24B
IMPALA CANADA LTD.	+82.85%	881M
A-MARK PRECIOUS METALS, INC.	+27.40%	881M
FURUYA METAL CO., LTD.	+12.36%	588M
HENAN HUANGHE WHIRLWIND CO., LTD.	-27.81%	537M
PYX RESOURCES LIMITED	-.--%	152M

Other Precious Metals & Minerals